Monday, 20 May 2019

Glenmark receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

15 March 2019 | News

It is a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda.

According to IQVIATM sales data for the 12 month period ending January 2019, the BenzaClin® Gel, 1%|5% market2 achieved annual sales of approximately $99.4 million.

Glenmark’s current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the U.S. FDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls